Sorry, you need to enable JavaScript to visit this website.
Animated pathogens
Animated pathogens

The fight is on

multi-drug resistant (mdr)
gram-negative bacteria are waging a war.

But help is at hand to support you in this fight. we believe that by combining our knowledge and expertise with yours, we can all work together to help prevent and treat hospital-acquired pneumonia (hap) and ventilator-associated pneumonia (vap) infections caused by mdr pathogens.

This resource is here to help the hap and vap community.

Scroll
Down!

Across the world, antimicrobial resistance in Hap/Vap is on the rise.1–3
The cause? MDR pathogens.1–3
In the short videos below you will:

  • hear about the experience of contracting hap/vap
  • learn what you can do to fight it in your clinical setting
  • discover some of the initiatives already underway to improve and protect global public health from this threat

Hap/Vap
accounts
for around

22%

of all hospital-acquired
infections4

Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
We’re putting hap/vap under the microscope: because by understanding it, we can defeat it. Together.
Pathogen
Pathogen
Pathogen

The patient’s experience: Contracting hap in the intensive care unit (ICU)

John Sperzel
“Pneumonia was different: I felt like it controlled me. I couldn't breathe, I felt like I was drowning.“
Close
John Sperzel

John Sperzel

John Sperzel

JOHN SPERZEL IS THE PRESIDENT AND CEO AT T2 BIOSYSTEMS. IN 2017, WHILST GOING ABOUT HIS EVERYDAY LIFE AS A HEALTHY, HIGH-PERFORMING HEALTHCARE EXECUTIVE, JOHN WAS FOUND UNCONSCIOUS AND UNRESPONSIVE. HE WAS RUSHED TO HOSPITAL WHERE HE WAS DIAGNOSED WITH GIANT CELL MYOCARDITIS, AN EXTREMELY RARE AND RAPIDLY FATAL DISORDER.

WHILE IN HOSPITAL JOHN UNDERWENT SEVERAL SURGERIES INCLUDING A MAJOR HEART TRANSPLANT OPERATION. HE SPENT LONG PERIODS OF TIME ON LIFE SUPPORT IN THE INTENSIVE CARE UNIT (ICU) WHERE HE BATTLED HOSPITAL ACQUIRED PNEUMONIA (HAP) AND AN MDR BACTERIAL INFECTION WHICH BECAME SEPTIC. JOHN SPENT A TOTAL OF 55 DAYS IN ICU BUT EVENTUALLY RECOVERED AND WAS ABLE TO RETURN HOME. AFTER SURVIVING A LIFE-THREATENING ILLNESS THAT RESULTED IN A HEART TRANSPLANT, HE IS PASSIONATE ABOUT SHARING HIS INCREDIBLE STORY.

Intensivist’s expert prognosis: Fighting hap/vap on
the frontline

Dr. Philippe Montravers
“The longer the delay for an appropriate treatment the higher the mortality rate.“4,5
Close
Dr. Philippe Montravers

DR PHILIPPE MONTRAVERS

DR PHILIPPE MONTRAVERS

DR PHILIPPE MONTRAVERS IS HEAD OF THE DEPARTMENT OF ANAESTHESIOLOGY AND SURGICAL INTENSIVE CARE UNIT AT THE ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS. HE HOLDS AN MD FROM THE BICHAT FACULTY OF MEDICINE, PARIS AND A PHD FROM THE UNIVERSITY OF PARIS VII.

HE WAS PRESIDENT OF THE CRITICAL CARE MEDICINE COMMITTEE OF THE SOCIÉTÉ FRANCAISE D'ANESTHÉSIE-RÉANIMATION (SFAR) (2010–11) AND HAS BEEN A MEMBER OF THE EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASE (ESCMID) AND OF THE EUROPEAN SOCIETY OF INTENSIVE CARE MEDICINE (ESICM) SINCE 2001.

DR MONTRAVERS HAS AN EXTENSIVE PUBLICATION RECORD, WITH OVER 300 AUTHORED AND CO-AUTHORED SCIENTIFIC PUBLICATIONS IN A VARIETY OF TOPICS INCLUDING PHARMACOKINETICS OF ANTIBIOTIC USE, POST-OPERATIVE CARE AND MDR BACTERIA RISK IN THE ICU. HIS CURRENT RESEARCH INTERESTS INCLUDE INVASIVE FUNGAL INFECTIONS, ANTI-INFECTIVE DE-ESCALATION, POST-OPERATIVE BACTERAEMIA AND PNEUMONIA. 

ANALYSIS FROM PFIZER'S SPECIALIST: FINDING SOLUTIONS FOR PNEUMONIA PREVENTION AND CURE

PAURUS IRANI MD
“How can we work together to address the growing threat of multidrug-resistant gram-negative infections?”
Close
Paurus Irani MD

Paurus Irani MD

Paurus Irani MD

SENIOR DIRECTOR – GLOBAL MEDICAL AFFAIRS, ANTI-INFECTIVES, PFIZER HOSPITAL BUSINESS UNIT. GLOBAL MEDICAL PRODUCT LEAD FOR CEFTAZIDIME/AVIBACTAM, LONDON, UK.

PAURUS IS AN MD FROM GRANT MEDICAL COLLEGE, UNIVERSITY OF MUMBAI, INDIA. HE HAS 23 YEARS EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY, ENCOMPASSING GLOBAL, COUNTRY AND REGIONAL ROLES ACROSS VARIOUS THERAPY AREAS INCLUDING CARDIOLOGY, UROLOGY, DIABETES AND ANTI-INFECTIVES.

Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen
Pathogen

HAP/VAP

Dangerous. Costly. But treatable!

A Resident Threat
HAP/VAP accounts for
Around
22%

of all hospital-acquired
infection4

Attacking your most
severely ill patients
Around
1/3

of nosocomial pneumonia cases -
mostly vap - occur in the icu5

Consider the
most common culprits
Around
50-80%

Of hap/vap infections are caused by mdr gram-negative bacteria. The most common of these pathogens are p.aeruginosa, extended-spectrum beta-lactamase (esbl)-producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae (cre)3,6

Pathogens
Pathogens
Act swiftly and appropriately
Early appropriate treatment, based on local epidemiology and risk factors for mdr pathogens, is extremely important3

What next!?

To learn more about Pfizer's treatment for HAP/VAP,

visit Pfizer's product page.

Type your country name or select from the menu:

  • Australia
  • Belgium
  • Vietnam
  • Brazil
  • Greece
  • Germany
  • Philippines
  • Netherlands
  • New Zealand
  • Spain

References

  1. MORRIS S, ET AL. ANTIBIOTICS (BASEL) 2020;9:196.
  2. PELEG AY, HOOPER DC. N ENGL J MED 2010;362:1804–13.
  3. CILLÓNIZ C, ET AL. CURR OPIN INFECT DIS 2019;32:656–62.
  4. KALIL AC, ET AL. CLIN INFECT DIS 2016;63:E61–E111.
  5. TORRES A, ET AL. EUR RESPIR J 2017;50:1700582.
  6. ZARAGOZA R, ET AL. CRITICAL CARE 2020;24:383.

PFIZER HELLAS SA. 2021 - ALL RIGHTS RESERVED.
PP-AIP-GRC-0080-JAN22

Close

We found a dedicated page for your location. Would you like to view it?